Treatment of Primary Ovarian Lymphoma in ALK-Positive Anaplastic Large-Cell Lymphoma

Clinical Scenario

This protocol addresses primary ovarian lymphoma occurring in the context of anaplastic lymphoma kinase-positive (ALK+) anaplastic large-cell lymphoma (ALCL) — a biologically distinct subtype with specific therapeutic considerations, particularly for relapsed or refractory disease.

Treatment Approach

Management in this setting involves targeted agents, with sequencing guided by prior therapy exposure. Additional chemotherapy combinations and consolidation strategies are considered depending on response and transplant eligibility.

The complete regimen, decision algorithm, and eligibility criteria are available in the full protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.annonc.2025.07.014

First-line treatment of ALK-positive ALCL:
For patients with r/r ALK-positive ALCL, BV is recommended if not received as first-line therapy [III, A].
For patients with ALK-positive ALCL refractory to BV, ALK inhibitors should be considered [III, A]. ChT (e.g. DHAP, ICE or IVAC-MTX) is also an option [III, B].
For transplant-eligible patients with PTCL or ALCL, consolidation with alloSCT can be considered [II, B].

View source ↗